Rubella clinical trials
The registry lists 92 studies for Rubella across more than 10 countries. 10 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-24.
Status
- Completed
- 74
- Not yet recruiting
- 6
- Recruiting
- 4
- Status unknown
- 4
- Terminated
- 3
- Withdrawn
- 1
Phase
- Phase 3
- 43
- Phase 4
- 22
- Phase 2
- 13
- Phase 1
- 2
Where
- United States
- 20
- China
- 7
- Puerto Rico
- 7
- Italy
- 7
- Germany
- 7
- Taiwan
- 6
Who runs them
GlaxoSmithKline (26) · Merck Sharp & Dohme LLC (17) · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (5) · Sanofi Pasteur, a Sanofi Company (5) · International Centre for Diarrhoeal Disease Research, Bangladesh (2) · Takeda (2) · Shanghai Institute Of Biological Products (2) · Centers for Disease Control and Prevention, China (2)
Studies
Recruiting first, then most recently updated. Showing 50 of 92 — search for more.
- Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation PatientsRecruitingNCT07195032Phase 41 country
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of AgeNot yet recruitingNCT07742644Phase 36 countries
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of AgeRecruitingNCT07406360Phase 31 country
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT073589101 country
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L VaccinesNot yet recruitingNCT073388511 country
- Prospective Clinical Registry for Evaluation of Exanthematous Infections and CoinfectionsNot yet recruitingNCT07112846
- Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 MonthsNot yet recruitingNCT06815835Phase 31 country
- Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster VaccinationRecruitingNCT05894395Phase 31 country
- Co-administration Study of OCV, TCV and MRNot yet recruitingNCT05771779Phase 3
- Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated VaccinesNot yet recruitingNCT05952505Phase 41 country
- Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMRCompletedNCT02325310Phase 41 country
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 MonthsCompletedNCT06399003Phase 31 country
- Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)CompletedNCT06331702Phase 41 country
- Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of AgeCompletedNCT03071575Phase 41 country
- A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of AgeCompletedNCT05630846Phase 25 countries
- The Effect of ShotBlocker on Pain and Satisfaction During Measles-Rubella-Mumps VaccinationCompletedNCT06762938Not applicable1 country
- Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, LiveCompletedNCT05161845Phase 41 country
- Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation TrialCompletedNCT04394689Phase 1/21 country
- The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella VaccineStatus unknownNCT05279248Phase 41 country
- MMR at 6 Months TrialCompletedNCT03780179Phase 41 country
- Immunity Duration Study Eight Years After Vaccination of Children 12 to 23 Months With the Triple Viral Vaccine (Measles, Mumps and Rubella)Status unknownNCT05154097
- Measles, Mumps, and Rubella (MMR) Immunity in College StudentsCompletedNCT009628191 country
- Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.CompletedNCT02699099Phase 31 country
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of LifeCompletedNCT01681992Phase 37 countries
- Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of AgeCompletedNCT02184572Phase 35 countries
- Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) VaccineCompletedNCT02880865Phase 41 country
- Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and RubellaCompletedNCT03148990Phase 2/31 country
- Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter WartsCompletedNCT03183765Phase 41 country
- Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of AgeCompletedNCT00861744Phase 22 countries
- Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)CompletedNCT04183114Phase 2/31 country
- Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of AgeCompletedNCT01702428Phase 36 countries
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of AgeCompletedNCT01621802Phase 33 countries
- Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working SeedsCompletedNCT00892775Phase 22 countries
- Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)CompletedNCT00092430Phase 3
- Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and ChickenpoxCompletedNCT00226499Phase 310 countries
- Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and ChildrenCompletedNCT03680417Phase 41 country
- Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) VaccinesCompletedNCT03368495Phase 41 country
- Coadministration of Measles-rubella and Rotavirus VaccinesCompletedNCT01700621Phase 41 country
- Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)CompletedNCT00326183Phase 4
- Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)CompletedNCT01536405Phase 3
- Clinical Trial for Measles - Rubella Combined Vaccine (MRVAC) Produced by POLYVAC (Phase III)CompletedNCT03713359Phase 3
- Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of AgeCompletedNCT00578175Phase 21 country
- Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy ChildrenCompletedNCT01506193Phase 31 country
- ProQuad® Intramuscular vs SubcutaneousCompletedNCT00402831Phase 3
- Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in ChildrenCompletedNCT00197015Phase 31 country
- Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTMCompletedNCT00969436Phase 31 country
- Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136CompletedNCT00751348Phase 31 country
- Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and OlderCompletedNCT02058563Phase 33 countries
- Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)CompletedNCT00432042Phase 32 countries
- Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Specified Drug-use Survey of Vaccinees After the Second VaccinationCompletedNCT021583641 country